Evidence map›Paper›PMID 40574704›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

PT

Liyan Fei, Yichun Pan, Jie Zhai, Tongqing Li, Yuxin Zhou, Sheyu Zhang, Juan Wei, Qian Hu, Xueying Liu, Lu Guo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. A target-activated AS1411 aptamer probe forFrontiers in bioengineering and biotechnology · 2026
    Article
  3. PTAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Liyan FeiSchool of Chemistry and Materials Science, University of Science and Technology of China, Hefei, 230026, P. R. China.ORCID 0000-0001-8147-204X
Yichun PanThe Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, P. R. China.
Jie ZhaiDepartment of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, 310022, P. R. China.
Tongqing LiThe Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, P. R. China.
Yuxin ZhouDepartment of Breast Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, 315040, P. R. China.
Sheyu ZhangThe Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, P. R. China.
Juan WeiThe Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, P. R. China.
Qian HuSchool of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 311300, P. R. China.
Xueying LiuThe Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, P. R. China.
Lu GuoThe Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, P. R. China.
Weizhu WuDepartment of Breast Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, 315040, P. R. China.
Yong WeiThe Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, P. R. China.
Qin WuThe Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, P. R. China.
Weihong TanThe Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, P. R. China.ORCID 0000-0002-8066-1524

Funding

Key Technologies Research and Development Program 2022YFC3400400Natural Science Foundation of Zhejiang Province 2023SDYXS0003Natural Science Foundation of Zhejiang Province LR22B050001Natural Science Foundation of Zhejiang Province YXD24B0701
6 · The paper itself

Abstract

The interaction between SCAF4 and RNA polymerase II (POLR2A) is crucial for proper mRNA termination, with its dysregulation leading to truncated mRNAs and nonfunctional proteins, impairing cellular growth. Despite its potential relevance, the role of this interaction in triple-negative breast cancer (TNBC) remains unexplored due to the lack of effective molecular tools. To address this, we employed SRiApt, an aptamer generated through the recently established Blocker-SELEX pipeline. Its biological stability is improved by phosphorothioate modifications to form PT

Indexed as

Aptamers, NucleotideRNA Polymerase IITriple Negative Breast NeoplasmsAnimalsCell Line, TumorCell ProliferationFemaleHumansMiceAptamers, NucleotideRNA Polymerase IIaptamerscancerspersonalized medicineprotein‐protein interactionstranscription factors

Identifiers

PMID40574704
PMCPMC12463048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.